Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250715103754/en/KalVista-Pharmaceuticals-Announces-UK-MHRA-Approval-of-EKTERLY-sebetralstat-First-and-Only-Oral-On-demand-Treatment-for-Hereditary-Angioedema

BUSINESSWIRE
15 Jul 2025

https://www.businesswire.com/news/home/20250710831184/en/KalVista-Pharmaceuticals-Provides-Operational-Update-and-Fiscal-Year-2025-Financial-Results

BUSINESSWIRE
10 Jul 2025

https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr

PRESS RELEASE
07 Jul 2025

https://www.prnewswire.com/news-releases/orsini-selected-as-specialty-pharmacy-partner-for-kalvistas-ekterly-sebetralstat-302498995.html

PR NEWSWIRE
07 Jul 2025

https://www.businesswire.com/news/home/20250626645779/en/KalVista-Pharmaceuticals-Enters-into-Licensing-Agreement-with-Pendopharm-to-Commercialize-Sebetralstat-for-HAE-in-Canada

BUSINESSWIRE
26 Jun 2025

https://www.businesswire.com/news/home/20250613608281/en/KalVista-Pharmaceuticals-Announces-FDA-Will-Not-Meet-PDUFA-Goal-Date-for-Sebetralstat-NDA-for-Hereditary-Angioedema-Due-to-FDA-Resource-Constraints

BUSINESSWIRE
13 Jun 2025